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Summary. Chikungunya virus is a reemerging arbovirus transmitted mainly by Aedes mosquitoes. As there are no specific 
treatments available, Chikungunya virus infection is a significant public health problem. This study investigated 120 extracts 
from selected medicinal plants for anti-Chikungunya virus activity. The plant materials were subjected to sequential solvent 
extraction to obtain six different extracts for each plant. The cytotoxicity and antiviral activity of each extract were examined 
using African monkey kidney epithelial (Vero) cells. The ethanol, methanol and chloroform extracts of Tradescantia 
spathacea (Commelinaceae) leaves showed the strongest cytopathic effect inhibition on Vero cells, resulting in cell 
viabilities of 92.6% ± 1.0% (512 µg/ml), 91.5% ± 1.7% (512 µg/ml) and 88.8% ± 2.4% (80 µg/ml) respectively. However, 
quantitative RT-PCR analysis revealed that the chloroform extract of Rhapis excelsa (Arecaceae) leaves resulted in the highest 
percentage of reduction of viral load (98.1%), followed by the ethyl acetate extract of Vernonia amygdalina (Compositae) 
leaves (95.5%). The corresponding 50% effective concentrations (EC50) and selectivity indices for these two extracts were 
29.9 ± 0.9 and 32.4 ± 1.3 µg/ml, and 5.4 and 5.1 respectively. Rhapis excelsa and Vernonia amygdalina could be sources of 
anti-Chikungunya virus agents. [Int Microbiol 19(3):175-182 (2016)]
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Introduction 
The Chikungunya virus is a reemerging mosquito-borne virus 
that belongs to the family Togaviridae, genus Alphavirus and 
causes Chikungunya fever in humans. The virus was first iso-
lated in 1952-1953, after an outbreak on the Makonde Pla-
teau, Tanzania [25]. The virus reemerged from the coastal ar-
eas of Kenya in 2004 with 5000 cases reported, and spread 
throughout the Indian Ocean islands (~270,000 cases in La 
Reunion island in 2005-2006), to India and Sri Langka (~1.4–
6.5 million cases in 2006-2007), Italy and France via import-
ed cases in 2007, Caribbean and Central and South America 
(~440,000 cases in 2014) and North America (>10,000 cases 
in 2013–2015), causing high morbidity in over 50 countries or 
territories [25,28]. 
The virus is transmitted to humans mainly by Aedes ae-
gypti and Aedes albopictus mosquitoes. The symptoms of 
Chikungunya fever, which include high fever, headaches, se-
vere back and joint pain, and rash, appear after 4–7 days. Al-
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though the symptoms are self-limiting, arthralgia or arthritis 
may persist for months or even years [15]. The name “Chi-
kungunya” is derived from a Makonde word that means “that 
which contorts or bends up” describing the distinctive sever-
ity of joint pains [31]. The medical treatment of Chikungunya 
virus infection relies on symptomatic relief as no specific 
treatment is available. Most of the deaths occur in neonates, 
adults with underlying medical conditions and the elderly. 
The Chikungunya virus mortality rate has been estimated to 
be 1:1000 [31]. Thus there is an urgent need to discover new 
antiviral compounds from natural resources especially me-
dicinal plants [32].
Virtually all cultures have relied, and continue to rely on 
medicinal plants for primary health care. Plants are rich 
source of phytochemicals which have been proven to have 
antimicrobial, antihypertensive, antidiabetic, antioxidative, 
hepatoprotective, cardioprotective and other therapeutic ac-
tivities. Around 50% of currently available drugs are derived 
from natural sources, using either natural substances or a syn-
thesized analogue of the natural product [17]. Reviews high-
lighting the potential and discovery of new drugs from me-
dicinal plants against viral infections have been published re-
cently [6,12]. This study was performed to investigate extracts 
of 20 selected medicinal plants from Malaysia for anti-Chi-
kungunya virus activity. 
Materials and methods
Plant materials. The aerial parts of Alternanthera sessilis, Asysta-
sia gangetica, Ipomoea aquatica, Persicaria odorata and Talinum frutico-
sum, the rhizome hairs of Cibotium barometz, the stem of Cissus quadrangu-
laris, and the leaves of the other thirteen plants were used in the study. Cibo-
tium barometz and Physalis minima were obtained from Cameron Highlands, 
Pahang; Ficus deltoidea and Tradescantia spathacea were harvested from 
Batu Pahat, Johor; Pereskia bleo was obtained from Lukut, Negeri Sembilan; 
and the remaining plants were obtained from different towns in the state of 
Perak in Malaysia. The identity of these plants was confirmed by Professor 
Hean Chooi Ong, an ethnobotanist at the Institute of Biological Sciences, 
Faculty of Science, University of Malaya, Malaysia, and the scientific names 
were further confirmed using the database “The Plant List” [www.the-
plantlist.org]. Specimen vouchers were prepared and deposited at the her-
barium of Faculty of Science, Universiti Tunku Abdul Rahman (Kampar 
campus) and the reference numbers assigned are listed in Table 1, which 
shows also the traditional uses of these plants (Table 1).
Preparation of plant extracts. Fresh plant materials were 
washed thoroughly with tap water. The plant samples were then blended and 
extracted sequentially with hexane, chloroform, ethyl acetate, ethanol, meth-
anol and distilled water at room temperature with agitation (100 rpm) using 
an orbital shaker (IKA-Werke KS 501, Germany). The maceration was car-
ried out for three cycles (one day per cycle). The filtrates were evaporated at 
40°C using a rotary evaporator (Buchi Rota-vapor R205, Switzerland), ex-
cept for the water extracts which were lyophilized using a freeze-dryer (Mar-
tin Christ Alpha, UK). The dried extracts were reconstituted in a dimethyl 
sulfoxide-ethanol mixture (60:40, v/v) to achieve a stock concentration of 
256 mg/ml. The extracts were then sterilized using 0.45 μm syringe filters and 
stored at −20°C prior to use.
Cell culture and virus propagation. African monkey 
kidney epithelial (Vero) cell line (CCL-81) was purchased from American 
Type Culture Collection. The cell line was used for propagation of Chikungu-
nya virus, cytotoxicity testing of plant extracts and cytopathic effect inhibi-
tion assay. The cell line was maintained in Dulbecco’s modified Eagle medi-
um (DMEM) (Sigma-Aldrich, St Louis, USA) supplemented with 5% of fetal 
bovine serum (Gibco, New York, USA), 1% of penicillin-streptomycin (Gib-
co, New York, USA) solution and sodium bicarbonate (Merck, Kenilworth, 
USA). Cultured Vero cells were incubated at 37°C in a humidified atmo-
sphere with 5% of carbon dioxide [9]. The medium was changed twice a 
week. The Chikungunya virus (accession number EU703761) used belonged 
to the Bagan Panchor strain (Asian genotype) and was provided by Professor 
Shamala Devi of Faculty of Medicine, University of Malaya, Malaysia. The 
virus was propagated in the Vero cells and harvested after cytopathic effect 
had developed and stored at –80°C prior to bioassay. 
Cytotoxicity assay. The cytotoxicity assay was carried out by 
seeding 4 × 104 Vero cells in each well of 96-well microtiter plates and incu-
bated for 24 h at 37°C in a humidified incubator with 5% CO2. Fresh DMEM 
medium (supplemented with 1% of fetal bovine serum) containing eight two-
fold serially diluted concentrations of extracts (640 to 5 µg/ml, 100 µl each) 
was added after 24 h of cell seeding while control wells contained cells with-
out the test sample. The microtiter plates were then incubated at 37°C in a 
humidified incubator with 5% CO2 for 72 h. The cell viability was determined 
by the neutral red uptake assay [22]. The assay was conducted in three inde-
pendent experiments with duplicates for each experiment.
Cytopathic effect inhibition assay. Non-toxic concen-
trations of the extracts with cell viability ≥ 90%, as determined from the cy-
totoxicity assay, were used in the cytopathic effect inhibition assay. Vero cells 
(4 × 104 cells/well) were seeded in 96-well microtiter plates and incubated at 
37°C and 5% CO2 for 24 h. Extracts of six concentrations, obtained by two-
fold serial dilution in DMEM (supplemented with 1% of fetal bovine serum) 
were then added together with Chikungunya virus at multiplicity of infection 
of 1. The virus titer was determined using the Reed and Muench method [21]. 
Medium (DMEM only), virus (cells with virus only) and cell (cells with me-
dium only) controls were included in each microtiter plate. Chloroquine (MP 
Biomedicals, Illkirch, France; purity > 99.9%) with a concentration range of 
0.39 to 12.4 µM was used as the positive control. The microtiter plates were 
then incubated at 37°C and 5% CO2 for 72 h. Determination of cell viability 
was carried out by the neutral red uptake assay [22]. The assay was performed 
in three independent experiments with duplicates for each experiment.
Quantitative RT-PCR. Quantitative RT-PCR was performed to 
determine the effects of selected active extracts (cell viability ≥ 70% in the 
cytopathic effect inhibition assay) on the Chikungunya virus replication by 
quantifying the viral genomic RNA copies based on the one-step SYBR 
Green based quantitative RT-PCR assay of Ali et al. [2]. The oligonucleotides 
were designed from the E1 region of Chikungunya virus and the sequence for 
the forward primer and reverse primer was 5′- CTCATACCGCATCCGCAT-
CAG-3′ and 5′-ACATTGGCCCCACAATGAATTTG-3′ respectively. Ten-
fold serial dilutions of a virus stock with a known copy number (1010 to 100) 
were used to generate a standard curve in which the Chikungunya virus RNA 
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standard was obtained by in vitro synthesis of RNA transcripts from DNA 
templates using MAXIscript in vitro kit (Ambion, Texas, USA). Sample 
RNAs were harvested from the extract-treated, virus-infected Vero cells and 
extracted using Invisorb spin virus RNA Mini Kit (Invitek, Berlin, Germa-
ny). The RT-PCR was conducted using the iScript One-Step RT-PCR kit 
(Biorad, Hercules, California, USA). The samples were assayed in a 25 µl 
reaction containing 2 µM of each forward and reverse primer, 5 µl of ex-
tracted RNA, 0.25 µl of reverse transcriptase, and 12.5 µl of SYBR Green 
Premix 2X. The amplifications were performed using Rotar Gene Q (Qiagen, 
Valencia, USA) with thermal cycling consisting of a reverse transcription 
step at 50°C for 30 min, initial denaturation at 95°C for 15 min, followed by 
40 cycles of amplification step and a final extension at 72°C for 10 min. The 
Chikungunya virus RNA copy number present in the extract-treated, virus-
infected cells was then quantified using the generated standard curve based 
on the cycle threshold (Ct) values against serially diluted Chikungunya virus 
stock. All samples were assayed in triplicates.
Data analysis. The percentages of cell viability at different extract 
concentrations were analyzed by one-way analysis of variance using IBM 
SPSS Statistics (Version 20) software. The significance level was set at P < 
0.05. Post hoc test, either with Tukey’s (equal variance assumed) or Dun-
nett’s (equal variance not assumed) test was further conducted to determine 
which concentration of an extract that produced significant result. 
Results
As a wide polarity range of solvents were used in the extrac-
tion, hexane and chloroform extracts can be grouped as non-
polar extracts, ethyl acetate extract as intermediate polar 
extract, and ethanol, methanol and water extracts as polar 
extracts. For the cytotoxicity study, nonpolar and intermedi-
ate polar extracts were generally more toxic to the Vero cells 
than polar extracts (data not shown) which prevented the 
evaluation of their potential antiviral effects at higher con-
centrations. Non-toxic concentrations (cell viability ≥ 90%) 
of an extract were then screened for cytopathic effect in-
hibitory activity.
We classified the cytopathic effect inhibitory activity as 
strong (cell viability ≥ 70%), moderate (cell viability from 
31% to 69%), and weak (cell viability ≤ 30%). Based on this 
classification, out of 120 extracts, only 9 showed strong in-
hibitory activity (Table 2) while 24 of the extracts showed 
moderate inhibitory activity. They were Alternanthera sessi-
lis (chloroform), Asystasia gangetica (ethyl acetate and etha-
nol), Catunaregam spinosa (ethyl acetate, ethanol and metha-
nol), Ficus deltoidea (ethanol and methanol), Ipomoea aquat-
ica (ethanol and methanol), Melastoma malabathricum (chlo-
roform, ethyl acetate, ethanol, methanol and water), Pepero-
mia pellucida (chloroform), Persicaria odorata (methanol), 
Physalis minima (ethanol and methanol), Rhapis excelsa 
(hexane, ethyl acetate, ethanol and methanol), and Vernonia 
amygdalina (chloroform). The rest of the extracts possessed 
weak inhibitory activity.
Nine extracts which showed strong cytopathic effect in-
hibitory activity were derived from five medicinal plants (Fig. 
1). The ethanol and methanol extracts of T. spathacea showed 
the strongest cytopathic effect inhibition, with cell viabilities 
of 92.6% ± 1.0% and 91.5% ± 1.7% (mean ± s.d., n = 3) re-
spectively at 512 µg/ml. This was followed by the chloroform 
extract of T. spathacea (88.8% ± 2.4% at 80 µg/ml), ethyl 
acetate extract of I. aquatica (87.2% ± 3.8% at 320 µg/ml) 
and methanol extract of V. amygdalina (81.9% ± 5.0% at 320 
µg/ml). The 50% effective concentrations (EC50), as deter-
mined from the plot of percentages of cell viability against 
extract concentrations, and selectivity indices for these ex-
tracts are shown in Table 2. The chloroform extract of R. ex-
celsa and the ethyl acetate extract of V. amygdalina had the 
lowest EC50 value and resulted in the highest selectivity indi-
ces (Table 2). The selectivity indices for the ethanol and meth-
anol extracts of T. spathacea could not be calculated as there 
was no significant cytotoxicity recorded for these two extracts 
even at the highest concentration tested (640 µg/ml).
Extracts which exhibited strong inhibitory activity were 
selected for Chikungunya viral load quantification by using 
quantitative RT-PCR and the results are shown in Table 3. The 
percentage of reduction in viral load of an active extract was 
compared with the virus control, in which the mean RNA 
copy number was 1.36 x 109 copies/µl after 72 h post infection 
without any extract treatment. The chloroform extract of R. 
excelsa produced the highest percentage of reduction of viral 
load with 98.1%, followed by the ethyl acetate extract of V. 
amygdalina at 95.5% and the ethanol extract of P. odorata at 
89.9%. In contrast, the ethanol and methanol extracts of T. 
spathacea were only able to reduce the viral load by 52.7% 
and 46.3% respectively (Table 3).
Discussion
A total of 120 extracts obtained from 20 medicinal plants be-
longing to 20 different families were investigated for the cyto-
toxic and anti-Chikungunya virus activities. A Vero cell line 
was used as it is one of the most common and well established 
mammalian cell lines used to assess the effects of chemicals, 
toxins and other substances at the molecular level [4]. The cell 
line is also known to be susceptible to many viruses, including 
Chikungunya virus [25], and displayed cytopathic effect upon 
infection.
The cytopathic effect inhibitory activity of an extract de-
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Fig. 1. Viability of African monkey kidney epithelial (Vero) cells co-incubated with the Chikungunya virus and the plant extracts at 37ºC and 5% CO2 for 
72 h. (A) Ipomoea aquatica, (B) Persicaria odorata, (C) Rhapis excelsa, (D) Tradescantia spathacea and (E) Vernonia amygdalina. The cell viability was 
determined by the neutral red uptake assay. The asterisk mark indicates significant difference (P < 0.05) when analyzed with one-way ANOVA test. The 
x-axis is displayed in log scale.
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pends on the plant species, type of solvent used for extraction, 
and extract concentration used in the assay. The extracts that 
possessed strong inhibitory activity against the Chikungunya 
virus were extracted mostly using chloroform, ethyl acetate, 
ethanol and methanol (Fig. 1). Although the ethanol and 
methanol extracts of Tradescantia spathacea exerted the 
strongest cytopathic effect inhibitory activity, the chloroform 
extract of Rhapis excelsa and ethyl acetate extract of Vernonia 
amygdalina had the highest percentage of reduction in the vi-
ral load compared to the virus control. This can be explained 
by the different targets of active extracts in inhibiting the vi-
rus. To control viral infection, various aspects of viruses, such 
as their structure, strategies for multiplication and propaga-
tion, and viral entry and release in the host cells could serve as 
potential targets for antiviral therapy [6]. The results from the 
viral load study suggest that the chloroform extract of R. ex-
celsa and ethyl acetate extract of V. amygdalina might have 
direct virucidal effect on the Chikungunya virus. While active 
extracts of T. spathacea, in addition to the virucidal effect, 
might also inhibit the release of mature virus from the infect-
ed cells and prevent the spread of the virus to other cells. 
Phytochemical analysis of the leaf of T. spathacea reveals 
the presence of secondary metabolites such as alkaloids, fla-
vonoids, glycosides, saponins and tannins [18]. The leaves of 
V. amygdalina contain alkaloids, anthraquinone, coumarins, 
glycosides, polyphenolics, reducing sugar, saponins, steroids, 
Table 2. Fifty percent cytotoxic concentration (CC50) and fifty percent effective concentration (EC50) of the medicinal plant extracts which have strong 
cytopathic effect inhibitory activity against the Chikungunya virus on African monkey kidney epithelial (Vero) cells
Plant Extract CC50a (µg/ml) EC50a (µg/ml) Selectivity indexb
Ipomoea aquatica Ethyl acetate > 640 227.0 ± 7.2 > 2.8
Persicaria odorata Ethanol 454.9 ± 6.9 132.7 ± 2.7 3.4
Rhapis excelsa Chloroform 161.5 ± 19.2 29.9 ± 0.9 5.4
Tradescantia spathacea Chloroform
Ethanol
Methanol
238.5 ± 3.1
NA
NA
60.2 ± 0.6
202.2 ± 2.1
179.0 ± 9.7
4.0
NA
NA
Vernonia amygdalina Ethyl acetate
Ethanol
Methanol
165.5 ± 9.2
272.4 ± 6.6
485.5 ± 2.8
32.4 ± 1.3
67.3 ± 1.2
199.9 ± 13.7
5.1
4.0
2.4
aResults are presented as mean ± standard deviation, n = 3. bSelectivity index is calculated as CC50/EC50. NA denotes could not be determined as there was 
no significant cytotoxicity at the highest concentration (640 µg/ml) used.
Table 3. Quantitative RT-PCR analysis of viral load in the African monkey kidney epithelial (Vero) cells co-incubated with the Chikungunya virus and 
selected medicinal plant extracts
Plant Extract Concentration (µg/ml) RNA copy numbera (copies/µl) Percentage of reductionb (%)
Ipomoea aquatica Ethyl acetate 320 4.78 x 108 ± 0.43x 108 64.9
Persicaria odorata Ethanol 160 1.37 x 108 ± 0.32 x 108 89.9
Rhapis excelsa Chloroform 40 0.26 x 108 ± 0.07 x108 98.1
Tradescantia spathacea Chloroform
Ethanol
Methanol
80
512
512
2.22 x 108 ± 0.71 x 108
6.44 x 108 ± 0.96 x 108
7.30 x 108 ± 0.44 x 108
83.7
52.7
46.3
Vernonia amygdalina Ethyl acetate
Ethanol
Methanol
80
160
320
0.61 x 108 ± 0.17 x 108
2.26 x 108 ± 2.86 x 108
2.35 x 108 ± 0.15 x 108
95.5
83.4
82.7
aResults are presented as mean ± standard deviation, n = 3. bThe percentage of reduction of the chikungunya virus RNA copy number is compared with 
the virus control (1.36 x 109 copies/μl) after 72 h post infection.
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and terpenoids [34]. Very little is known about secondary me-
tabolites of R. excelsa. Hassanein et al. [11] reported the isola-
tion of four flavonoids, i.e., apigenin-8-C-glucoside (vitexin), 
apigenin-6,8-di-C-β-glucopyranoside (vicenin-2), luteolin-
6-C-glucoside (isoorientin) and luteolin-8-C-glucoside (ori-
entin) from the leaves of R. excelsa. Some phytochemicals in 
these plants may account for the antiviral activity observed in 
this study. The flavonoid silymarin was recently identified to 
possess significant anti-Chikungunya virus activity at the 
post-entry stages [14]. Andrographolide, a bicyclic diterpe-
noid lactone from the plant Andrographis paniculata is effec-
tive in inhibiting Chikungunya virus replication [32].
Treatment with the leaf extracts of Rhapis excelsa and 
Vernonia amygdalina resulted in the highest percentage of re-
duction in the viral load and could be a potential source of 
novel anti-Chikungunya virus compounds. Thus further ef-
forts are needed to isolate and characterize the active com-
pounds, and to investigate the mechanism of their action. 
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